Follow Kenvue to never miss an important update.
After Kenvue reported its October results, we updated our fair value. We changed our rating from Buy to Watch. We have added the risks of integrating with Kimberly-Clark and the temporary nature of tax refunds on imports to what we track. We also lowered our assumption for annual sales growth at the company's existing brands to 2.9%.
The merger between Kenvue and Kimberly-Clark closed on November 2, 2026. Under the final terms, each share of Kenvue was converted into 0.14625 shares of Kimberly-Clark stock plus $3.50 in cash. This marks the end of Kenvue's short life as an independent company after its spin-off from Johnson & Johnson.
For owners, the focus now shifts to how well Kimberly-Clark can integrate these health brands into its own global supply chain. The company has already terminated Kenvue’s previous credit lines and incentive plans as it folds the business into its own operations. Kenvue will be replaced in the S&P 500 index as it is no longer a standalone public entity.
Source: 8-K filing
In its final report before being acquired, Kenvue posted $3.89 billion in revenue, slightly ahead of what analysts expected. Profits came in at $0.29 per share, matching expectations. The company saw steady demand for its self-care and essential health products, which helped expand its profit margins.
These results show a business that was finding its footing just as it reached the finish line of its merger. By growing organic sales, a measure that excludes the impact of currency swings or brand sales, by nearly 3 percent, Kenvue proved its core brands like Tylenol remain resilient. This momentum gives Kimberly-Clark a healthy foundation to build on as it takes over the portfolio.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Because Kenvue is being acquired by Kimberly-Clark, it will no longer exist as a separate stock. As a result, S&P Dow Jones Indices is removing Kenvue from the S&P 500, a list of the largest U.S. companies. Okta Inc. will take its place in the index before trading opens on Wednesday.
This is a routine mechanical change that happens whenever a member of the index is bought out. For investors, it simply confirms that Kenvue is transitioning from a standalone investment into part of the larger Kimberly-Clark business.
Source: PRNewsWire
The European Commission has approved the acquisition of Kenvue by Kimberly-Clark. To get the green light, the companies agreed to sell off certain parts of their business to ensure they don't have too much control over the tampon market in Czechia, Estonia, and Slovakia.
This was one of the final major hurdles for the deal. By addressing these specific competition worries, the companies cleared the path to combine their massive portfolios of household brands. It signals that regulators are satisfied the merger won't unfairly limit choices for consumers in those regions.
Source: WSJ
Management has a history of hitting their targets by a hair. It shows they set a predictable bar and clear it, though they rarely deliver a massive surprise.
| Expectation | |
|---|---|
| EPS | $0.28 |
| Revenue | $3.89B |